In the first public instance of a US biomedical institution sanctioning its own researchers for alleged threats of foreign influence, MD Anderson Cancer Cancer Center is ousting three scientists it says who have violated conflict of interest policies.

The prestigious Houston research hospital has initiated the termination processes in response to NIH letters requesting that it look into the conduct of specific researchers. The actions also follow some ongoing engagement with the FBI that dated back at least two years, according to the Houston Chronicle and Science, which first reported the news.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.Email:Access is subject to the terms in our Privacy Policy.

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.Email:Access is subject to the terms in our Privacy Policy.

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.